According to GlobalData’s medical device pipeline database, 15 Brain Natriuretic Peptide (BNP) Point of Care (POC) Tests devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, seven are in active development, while the remaining eight are in an inactive stage of development. There are six products in the early stages of development, and the remaining one is in the late stages of development.
Brain Natriuretic Peptide (BNP), also known as B-type natriuretic peptide or Ventricular Natriuretic Peptide is a 32-amino acid polypeptide secreted by heart ventricles in response to excessive stretching of heart muscle cells (cardiomyocytes). BNP is mostly used in diagnosis of heart failure. In BNP POC tests a small amount of blood is added to a premix of chemicals and 2-3 drops of this mixture is poured onto the test strips to provide immediate results during patient consultation. One unit refers to one POC test.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
See Also:
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Brain Natriuretic Peptide (BNP) Point of Care (POC) Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Brain Natriuretic Peptide (BNP) Point of Care (POC) Tests devices. Overall, most of these Brain Natriuretic Peptide (BNP) Point of Care (POC) Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Brain Natriuretic Peptide (BNP) Point of Care (POC) Tests include Abionic, Accel Diagnostics, Atonomics, Biostealth, Bluejay Diagnostics, Edan Instruments, ET Healthcare, Group K Diagnostics, LumiraDx and National Technology and Engineering Solutions of Sandia.
For a complete picture of the developmental pipeline for Brain Natriuretic Peptide (BNP) Point of Care (POC) Tests devices, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
